AMGXF.US AnGes Inc

Healthcare Biotechnology USA Stocks
0.3602 USD
Close of Nov 13, 2026
0.3602 0.3602
Market cap
USD 144M
P/E
-
P/B
0.73x
ROE
-2,639.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AMGXF.US undervalued?

Graham number

The Graham number of AnGes Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AnGes Inc fundamental analysis

No fundamental analysis for AnGes Inc yet.

AnGes Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AnGes Inc

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The compan…

Full company profile